Cancer diagnosis and monitoring; HSP70-exosomes; Liquid biopsy; Pilot study; Solid tumours
Abstract :
[en] BACKGROUND: Cancer is the second leading cause of death globally. Early detection and disease management lead to a better survival rate. Consequently, discovery of novel methods in cancer early diagnosis is a field of active research. Minimally invasive liquid biopsies are generating growing interest. Circulating tumour cells (CTCs) have been identified in patients' blood; nevertheless, these cells are rare and heterogeneous. Exosomes are extracellular nanovesicles released into the extracellular environment via the endosomal vesicle pathway and found in different body fluids. Exosomes deliver bioactive cargo such as proteins, mRNA and miRNA to recipient cells in the tumour environment. We have recently shown that heat shock protein 70 (HSP70) is detected in the membrane of tumour-derived exosomes, in contrast to normal cells. One single cancer cell can release thousands of HSP70-exosomes, facilitating detection. The aim of the pilot study ExoDiag is to determine whether it is possible to detect and quantify HSP70-exosomes in blood in patients with solid cancers. METHODS: Bicentric pilot study that will include 60 adult patients with metastatic and non-metastatic solid tumours and 20 healthy volunteers. Exosomes will be isolated from blood and urine samples, and HSP70 concentration will be determined. Patients will be followed for 1 year. The study is sponsored by Georges-François Leclerc Centre and is currently ongoing. DISCUSSION: We expect to demonstrate that HSP70-exosomes could be a powerful tool to diagnose cancer and to guide clinicians in therapeutic decision-making, improving patient's care. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT02662621. Registered 20 January 2016, https://clinicaltrials.gov/ct2/show/study/NCT02662621?term=NCT02662621&rank=1.
Disciplines :
Oncology
Author, co-author :
Chanteloup, Gaétan; 1Laboratoire d'Excellence LipSTIC, UMR 1231, INSERM, Dijon, France. GRID: ; 2Faculty of Medicine and Pharmacy, University of Burgundy, Dijon, France. GRID:
Cordonnier, Marine; 1Laboratoire d'Excellence LipSTIC, UMR 1231, INSERM, Dijon, France. GRID: ; 2Faculty of Medicine and Pharmacy, University of Burgundy, Dijon, France. GRID:
Isambert, Nicolas; 3Pôle Régional de Cancérologie, CHU de Poitiers Poitiers, INSERM U-1084,
Bertaut, Aurélie; Unit of Methodology, Biostatistics and Data Management, Georges-François Leclerc
Marcion, Guillaume ; Université de Liège - ULiège > GIGA > GIGA I3 - Hematology ; 1Laboratoire d'Excellence LipSTIC, UMR 1231, INSERM, Dijon, France. GRID: ; 2Faculty of Medicine and Pharmacy, University of Burgundy, Dijon, France. GRID:
Garrido, Carmen; 1Laboratoire d'Excellence LipSTIC, UMR 1231, INSERM, Dijon, France. GRID: ; 2Faculty of Medicine and Pharmacy, University of Burgundy, Dijon, France. GRID: ; Department of Medical Oncology, Early Phase Unit, Georges-François Leclerc
Gobbo, Jessica; 1Laboratoire d'Excellence LipSTIC, UMR 1231, INSERM, Dijon, France. GRID: ; 2Faculty of Medicine and Pharmacy, University of Burgundy, Dijon, France. GRID: ; 5CIC-1432, INSERM, Dijon, France. GRID: grid.7429.8. ISNI: 0000000121866389 ; Department of Medical Oncology, Early Phase Unit, Georges-François Leclerc
Language :
English
Title :
Membrane-bound exosomal HSP70 as a biomarker for detection and monitoring of malignant solid tumours: a pilot study.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 0(0). doi: https://doi.org/10.3322/caac.21492.
Cui S, Cheng Z, Qin W, Jiang L. Exosomes as a liquid biopsy for lung cancer. Lung Cancer. 2018;116:46-54. https://doi.org/10.1016/j.lungcan.2017.12.012.
Palmirotta R, Lovero D, Cafforio P, et al. Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology: Ther Adv Med Oncol. August 2018. doi: https://doi.org/10.1177/1758835918794630.
Young R, Pailler E, Billiot F, et al. Circulating tumor cells in lung cancer. Acta Cytol. 2012;56(6):655-60. https://doi.org/10.1159/000345182.
Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow-up time point duringtherapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12(14):4218-24. https://doi.org/10.1158/1078-0432.CCR-05-2821.
Kowalik A, Kowalewska M, Góźdź S. Current approaches for avoiding the limitations of circulating tumor cells detection methods - implications for diagnosis and treatment of patients with solid tumors. Transl Res. 2017;185:58-84.e15. https://doi.org/10.1016/j.trsl.2017.04.002.
Pisitkun T, Shen R-F, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci U S A. 2004;101(36):13368-73. https://doi.org/10.1073/pnas.0403453101.
Taylor DD, Akyol S, Gercel-Taylor C. Pregnancy-associated exosomes and their modulation of T cell signaling. J Immunol. 2006;176(3):1534-42. https://doi.org/10.4049/jimmunol.176.3.1534.
Melo SA, Luecke LB, Kahlert C, et al. Glypican1 identifies cancer exosomes and facilitates early detection of cancer. Nature. 2015;523(7559):177-82. https://doi.org/10.1038/nature14581.
Gobbo J, Marcion G, Cordonnier M, et al. Restoring anticancer immune response by targeting tumor-derived exosomes with a HSP70 peptide aptamer. JNCI J Natl Cancer Inst. 2016;108:3. https://doi.org/10.1093/jnci/djv330.
Lanneau D, de Thonel A, Maurel S, Didelot C, Garrido C. Apoptosis versus cell differentiation. Prion. 2007;1(1):53-60.
Lanneau D, Wettstein G, Bonniaud P, Garrido C. Heat shock proteins: cell protection through protein triage. Sci World J. 2010;10:1543-52. https://doi.org/10.1100/tsw.2010.152.
Multhoff G. Heat shock protein 70 (Hsp70): membrane location, export and immunological relevance. Methods San Diego Calif. 2007;43(3):229-37. https://doi.org/10.1016/j.ymeth.2007.06.006.
Gibert B, Eckel B, Gonin V, et al. Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo. Br J Cancer. 2012;107(1):63-70. https://doi.org/10.1038/bjc.2012.188.
Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 2005;10(2):86-103.
Murphy ME. The HSP70 family and cancer. Carcinogenesis. 2013;34(6):1181-8. https://doi.org/10.1093/carcin/bgt111.
Cordonnier M, Chanteloup G, Isambert N, et al. Exosomes in cancer theranostic: diamonds in the rough. Cell Adhes Migr. 2017;11(2):151-63. https://doi.org/10.1080/19336918.2016.1250999.
Chalmin F, Ladoire S, Mignot G, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest. 2010;120(2):457-71. https://doi.org/10.1172/JCI40483.
Gong J, Weng D, Eguchi T, et al. Targeting the hsp70 gene delays mammary tumor initiation and inhibits tumor cell metastasis. Oncogene. 2015;34(43):5460-71. https://doi.org/10.1038/onc.2015.1.
Riches A, Campbell E, Borger E, Powis S. Regulation of exosome release from mammary epithelial and breast cancer cells - a new regulatory pathway. Eur J Cancer. 2014;50(5):1025-34. https://doi.org/10.1016/j.ejca.2013.12.019.
